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CHAPTER III
Obesity-induced chronic inflammation in high fat 
diet challenged C57BL/6J mice is associated with 
acceleration of age-dependent renal amyloidosis 
Roel A. van der Heijden, Johan Bijzet, Wouter C. Meijers, Gopala K. Yakala, 
Robert Kleemann, Tri Q. Nguyen, Rudolf A. de Boer, Casper G. Schalkwijk, 
Bouke P.C. Hazenberg, Uwe J. F. Tietge and Peter Heeringa
Scientific Reports. 2015 Nov 13;5:16474
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ABSTRACT
Obesity-induced inflammation presumably accelerates the development of chronic 
kidney diseases. However, little is known about the sequence of these inflammatory 
events and their contribution to renal pathology. We investigated the effects of obesity 
on the evolution of age-dependent renal complications in mice in conjunction with the 
development of renal and systemic low-grade inflammation (LGI). 
C57BL/6J mice susceptible to develop age-dependent sclerotic pathologies with amyloid 
features in the kidney, were fed low (10% lard) or high-fat diets (45% lard) for 24, 40 and 
52 weeks. HFD-feeding induced overt adiposity, altered lipid and insulin homeostasis, 
increased systemic LGI and  adipokine release. HFD-feeding also caused renal 
upregulation of pro-inflammatory genes, infiltrating macrophages, collagen I protein, 
increased urinary albumin and NGAL levels. HFD-feeding severely aggravated age-
dependent structural changes in the kidney. Remarkably, enhanced amyloid deposition 
rather than sclerosis was observed. The degree of amyloidosis correlated significantly 
with body weight. Amyloid deposits stained positive for serum amyloid A whose plasma 
levels were chronically elevated in HFD mice.
Our data indicate obesity-induced chronic inflammation as a risk factor for the 
acceleration of age-dependent renal amyloidosis and functional impairment in mice, and 































Renal aging is characterized by various structural changes that manifest as 
glomerulosclerosis (GS), tubular atrophy and interstitial fibrosis 1. These age-related 
changes ultimately lead to a decline in renal function 2 and may result in chronic 
kidney disease (CKD). As life expectancy continues to increase, the prevalence of CKD 
in the aging population is likely to increase as well 3,4. Besides age, environment and 
lifestyle are important risk factors for CKD. More specifically, the alarming increase in 
(morbid) obesity, resulting from our changing dietary habits 5 and sedentary lifestyles 
6, has been shown to increase the incidence of CKD 7,8. Although the development and 
progression of CKD is clearly multifactorial, compelling evidence points towards low-
grade inflammation as a driving force 9,10. Whereas aging and obesity are both associated 
with a state of chronic inflammation 11,12, obesity-induced chronic inflammation may be 
established much earlier in life 13 and hence its detrimental effects are induced earlier and 
are longer lasting than those observed with aging.
The exact mechanisms by which chronic inflammation contributes to CKD remain to be 
elucidated. However, increasing evidence supports a crucial role of renal macrophages. 
As macrophages infiltrate and accumulate in the interstitium, pro-fibrotic factors are 
released locally, promoting the deposition of extracellular matrix proteins such as 
collagen type I eventually leading to structural changes 14. These structural changes are 
associated with impaired vaso-contractility and disturbance of the filtrating capacity of 
the kidney 15.
The evolution of obesity-associated CKD in humans is difficult to study since clinical 
disease hallmarks, such as increased albuminuria and decreased eGFR, arise at a late 
stage, often when irreversible organ impairment has already taken place. Therefore, 
from a diagnostic as well as therapeutic perspective, disseminating the various stages  of 
disease development is crucial. 
The aim of the current study was to provide insight into the onset and evolution of both 
obesity- and age-associated renal pathologies and how these pathologies manifest at 
the functional and systemic level. We hypothesized that a chronic, obesity-enhanced 
elevation of systemic pro-inflammatory factors would accelerate the appearance and 
progression of age-associated renal dysfunction. To address this hypothesis, in C57BL/6j 
mice prone to develop age-dependent renal pathologies 16 we established and monitored 
high fat diet-induced obesity (DIO) for a period of 52 weeks, compared the structural 
and functional alterations in the kidneys to age-matched low fat diet controls and linked 
these alterations to local and systemic inflammatory parameters.
50 
METHODS
Mice, diets and housing conditions
Male C57BL/6J (JAX) mice (99 in total) at the age of 6 weeks, weighing 20 ±2 grams, 
were obtained from Charles River (Charles River Laboratories, France). Mice were single 
housed and during the entire experiment kept on a 12 hour light:12 hour dark cycle 
with ad libitum access to food and water. After arrival all mice received a low-fat control 
diet (LFD; 10% lard; Research Diets, NJ, USA; D12450HY) for six weeks after which 
54 mice switched to a high-fat diet (HFD; 45% lard; Research Diets; D12451). LFD and 
HFD mice were randomly divided in three groups, receiving either 24, 40 or 52 weeks 
of LFD control or HFD diet. Bodyweight was determined at regular intervals. To ensure 
experiments were conducted in a chronic state of obesity, mice that exhibited a >15% 
weight loss compared to their peak weight, were excluded from all analyses. Six mice 
were excluded from the study due to the development of dermatitis, that is n=2 in the 
HFD24 group, n=3 in the HFD52 group, and n=1 in the LFD52 cohort. The experimental 
study design with final cohort sizes is given in Suppl. Fig. 4. All experiments were 
approved by the Committee on Animal Experimentation of the University of Groningen 
and were conducted in accordance to the Dutch Law on Animal Experimentation 
(WOD), following international guidelines on animal experimentation. Certain data, 
namely body weight development over time and plasma glucose, insulin, cholesterol 
and triglyceride levels were published previously 17, but have been included here as well 
for completeness of the basic phenotypic characterization.
Blood collection and sacrifice procedure
Prior to sacrifice mice were fasted for 6 hours (8:00-14:00). Mice were anesthetized 
by isoflurane (2% in oxygen). Aorta and left ventricle hemodynamic measurements 
were performed using a Millar catheter (Mikro-tip 1.4F; SPR-839, Millar Instruments, 
Houston, TX, USA) via the right carotid artery in n=8 mice per experimental group, 
as described elsewhere 18. Hereafter, whole blood samples were collected by cardiac 
puncture, immediately transferred to EDTA coated tubes (Sarstedt) and put on ice. 
Samples were spun down (5˚C, 3000 rpm) and plasma was isolated and stored at -80C. 
The lower part of the aorta was cut and the circulation was flushed with NaCl. Kidneys, 
heart (compartmentalized), adipose tissue (mesenteric, gonadal and perirenal depots) 
were isolated, weighed and partially snap frozen and stored at -80˚C and partially fixed 































Paraffin embedded kidney sections (4µm), were fixed in aceton and deparaffinized 
as described elsewhere19, and stained for Masson’s trichrome (MT) and periodic acid 
Schiff’s (PAS). MT and PAS sections were assessed by brightfield microscopy and 
representative pictures of cortical regions and individual glomeruli were taken at 100x 
and 400x magnification respectively (Olympus BX50/DP72, Olympus, Shinjuku, Tokio, 
Japan). 
Amyloid staining and quantification
Congo red (CR) dye has been  acknowledged by the International Society of Amyloidosis 
as the golden standard for detection of amyloid 20. CR  staining was executed according 
to internationally accepted staining procedures 21. Briefly, paraffin sections (8 μm) 
were deparaffinized and rehydrated as described previously, followed by staining 
with Mayer’s Hemalum for 15 seconds and destained under running tapwater for 
10 minutes. Hereafter sections were first stained for 30 minutes with freshly filtered 
solution 1 (saturated solution of NaCl (2%) in 80% Ethanol and 0.01% NaOH) followed 
by staining for 30 minutes with freshly filtered solution 2 (saturated solution of NaCl 
(2%) and Congo red (1%; Sigma Aldrich) in 80% Ethanol and 0.01% NaOH). Slides were 
washed twice with Ethanol followed by two washes with demineralized water. Slides 
were covered with Kaiser’s glycerol gelatin and a coverglass. Sections were assessed by 
polarized light, with apple-green birefringence confirming the amyloid nature of Congo 
Red stained tissues.
CR dye was quantified in glomerular and interstitial/tubular regions using Spectral 
Imaging (Nuance FX, PerkinElmer, Waltham, MA, USA). In short, approximately 6 
cortical fields were selected containing a total of 30 glomeruli. The CR specific spectrum 
was determined and spectral images were transformed to black and white for further 
quantification of area and intensity using Aperio ImageScope Software (Aperio 
Technologies, CA, USA). Distinction was made between intra and –extraglomerular 
areas and data are presented as  % CR positive  area (amyloid score).
Immunohistochemistry
All immunohistochemical stainings were performed on air-dried renal cryo sections 
(4µm). Sections were incubated with primary antibodies for rat-anti-mouse CD68 (FA11 
clone, Serotec, Puchheim, Germany), rabbit-anti-mouse Collagen I (Abcam, Cambridge, 
UK) or goat-anti-mouse SAA (R&D systems, Abingdon, UK), combined with secondary 
unlabeled rabbit-anti-rat for CD68 (Vector laboratories, Burlingame, CA, USA), and rabbit-
anti-goat for SAA (Dako, Heverlee, Belgium) antibodies respectively. A commercially 
available AEC kit, using Anti-Rb HRP polymer was used to visualize protein expression 
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(Dako). Sections were digitalized at 400x magnification using Hamamatsu NDP slide 
scanner (Nanozoomer 2.0HT, Hamamatsu Photonics, Hamamatsu, Japan) and six 
matched CD68 and collagen I cortical sections were selected at 200x magnification from 
approximately 10 mice per experimental group per time point. SAA was only stained 
on sections from the LFD52 and HFD52 cohort. Staining was quantified using Aperio 
ImageScope Software (Aperio Technologies).
Urine collection and analyses 
Two weeks prior to sacrifice mice were transferred to metabolic cages for 20h urine 
collection (12:00 p.m. day 1 until 8:00 a.m. day 2). Mice had ad libitum access to food 
and water. Samples were collected and spun down at 15.000rpm, urine was transferred 
and volume was determined. Urinary albumin (Bethyl laboratories, Montgomery, TX, 
USA), NGAL (R&D systems) and KIM-1 (R&D systems) concentration were determined 
by ELISA, and adjusted for urinary volume.
Plasma analyses
Plasma samples were collected as detailed above. All analyses were performed using 
commercially available kits and according to manufacturer’s instructions unless stated 
otherwise. Plasma leptin and adiponectin were determined by ELISA (R&D systems), 
cholesterol and triglycerides by biochemical assays (cat.no. 11489437 and 11488872 
respectively Roche Diagnostics, Almere, The Netherlands). Glucose was determined 
using a hand held glucometer (LifeScan, Milpitas, CA, USA) directly after blood was 
drawn. Insulin was determined by ELISA (Alpco, Tilburg, The Netherlands). Blood 
urea nitrate was determined by biochemical assay (QuantiChrom Urea Assay Kit, 
BioAssaySystems, Hayward, CA, USA). Inflammatory markers TNF-α, IL-6, IL-1β were 
measured as part of a Mesoscale discovery 10-plex multispot Mouse cytokine assay 
(Gaithersburg, USA). Mouse plasma MCP-1 (Thermo-Fisher scientific, Pittsburgh, PA) 
and mouse Serum Amyloid A protein (Tridelta, Maynooth, Ireland) were determined by 
ELISA.
RNA isolation and RT-qPCR
RNA was isolated from thirty 5µm thin cryo sectons using Rneasy Mini plus Kit (Qiagen, 
Westburg, Leusden, The Netherlands) according to the manufacturer’s instruction. 
Procedures for determining RNA integrity, quality and quantity as well as cDNA 
synthesis can be found elsewhere 19. Expression of selected genes was performed by 
Assays-On-Demand primer probe sets (Tnf; Mm00443258_m1 , Mcp-1; Mm00441242_m1, 
IL-6; Mm00446190_m1, IL-1β; Mm00434228_m1, Ppia; Mm02342430_g1, AB Systems, 





























FPLC and Western blot
Pooled plasma samples for LFD52 and HFD52 were subjected to fast protein liquid 
chromatography (FPLC) gel filtration using a Superose 6 column (GE Healthcare, 
Hoevelaken, The Netherlands) as described elsewhere 22. Fractions corresponding to 
HDL were pooled to assess SAA protein concentration. Protein concentrations of pooled 
samples were measured using BCA assay (Pierce). Equal amounts of protein were 
separated by electrophoresis (Beckman Instruments, Brea, CA, USA) and blotted onto 
nitrocellulose membrane. After blocking, membranes were incubated with primary 
mouse SAA antibody (R&D systems) followed by incubation with appropriate secondary 
antibodies. 
Statistical analyses
Data were analyzed using GraphPad Prism (version 5.00, GraphPad Software, San Diego, 
CA, USA). Non-parametric Mann-Whitney U tests were performed for comparing LFD 
and HFD groups within a time point, and Kruskall Wallis ANOVA with Dunn’s post hoc 
test was used to determine differences between time points within the designated diet. 
Correlation analyses were performed using Spearman r. p-values lower than 0.05 were 
considered significant. Data are expressed as mean ± standard error of the mean (SEM). 
Significance level was set at p<0.05.
RESULTS
HFD-feeding leads to adiposity and metabolic dysfunction 
In low fat diet (LFD) and high fat diet (HFD) mice, body weight increased gradually 
over time, reaching a plateau at 36 weeks. The average body weight in HFD mice was 
significantly higher than in LFD mice from 6 weeks onwards (Fig. 1A). All HFD mice 
showed a marked increase in kidney weight and adipose tissue mass for gonadal, 
perirenal and mesenteric depots analyzed at all time points as compared to LFD mice 
(Fig. 1B-C). In HFD mice plasma levels of leptin were strongly increased at all three 
time points when compared to LFD mice (Fig. 1D). Adiponectin, a factor known to be 
inversely correlated with obesity, gradually decreased in HFD mice, but no significant 
difference with LFD mice was reached (p=0.07 at 40w; Fig. 1E). 
Adiposity is associated with the release of excess lipids into the circulation resulting in 
systemic hyperlipidemia. In HFD mice, plasma cholesterol was significantly increased 
at all time points compared to LFD mice (Fig. 2A), whereas elevated plasma triglyceride 
levels were detected at 40w (Fig. 2B). HFD-increased insulin levels were detected but no 
significant changes in plasma glucose levels were observed throughout the experimental 
period (Fig. 2C-D). 
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HFD-induced obesity aggravates age-dependent albuminuria and enhances urinary 
NGAL levels
We observed an age-dependent increase in albuminuria, which was significantly 
aggravated by HFD (Fig. 3A). Blood urea nitrogen (BUN) levels did not show age-
dependent alterations nor differences between dietary groups (Fig. 3B). Interestingly, 
neutrophil gelatinase-associated lipocalin (NGAL) levels, a protein secreted upon kidney 
injury, were already significantly higher in urine samples of HFD mice compared to LFD 
mice from 24w onwards, but did not change over time (Fig. 3C). In contrast, urinary 
levels of kidney injury molecule 1 (KIM-1), a marker for kidney repair upon injury, did 
not differ between the diet groups, nor did they change over time (Fig. 3D).
Figure 1. Weight gain and adiposity with aging and HFD-feeding. (A) Gradual age-associated increase 
in body weight (23.9± 0.2 g at baseline), (B) total kidney weight and (C) adipose depot weights were 
enhanced by prolonged HFD-feeding. (D) Adiposity was further reflected by an increase in plasma leptin. 
(E) Decrease in plasma adiponectin was observed with aging but did not reach significance between LFD 
and HFD. Data are expressed as mean ±SEM. Dotted lines represent baseline values for leptin (0.13± 0.05 
ng/ml) and adiponectin (11.18± 0.65 ng/ml). Significance level set as p<0.05. *=significantly different 
from LFD same time point, †=significantly different from same diet 24w, ‡=significantly different from 





























Since increased blood pressure (BP) is a main driver of renal injury and dysfunction, BP 
was measured invasively. No significant increases in central BP were observed at any 
time point in HFD mice compared to LFD mice (Suppl. 1A). Interestingly, despite the 
absence of hypertension, mild left ventricular hypertrophy did occur (Suppl. 1B), with 
an increase in various early-onset tissue markers for left ventricular hypertrophy (Suppl. 
1D-F), albeit with normal systolic cardiac performance (Suppl. 1C).
Figure 2. Metabolic dysfunction with aging and HFD feeding. (A) HFD-feeding leads to hyperlipidemia 
as evidenced by a significant increase in plasma cholesterol and (B) plasma triglyceride levels. (C) Blood 
glucose levels did not change over time and were not different between LFD and HFD mice, but (D) were 
paralleled by elevated plasma insulin levels in HFD mice. Data are expressed as mean ±SEM. Dotted lines 
represent baseline values for cholesterol (2.21± 0.06 mM), triglycerides (0.34± 0.03 mM), glucose (7.34± 
0.32 mM) and insulin (0.43± 0.08 ng/µl). Significance level set at p<0.05. *=significantly different from 
LFD same time point, †=significantly different from same diet 24w, ‡=significantly different from same 
diet 40w.
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Age-dependent renal sclerosis is aggravated by HFD-induced obesity and displays 
features of amyloidosis 
Histological analysis of renal tissue using Periodic Acid Schiff’s (PAS) and Masson-
trichrome (MT) stainings revealed an age-associated, progressive sclerotic phenotype. 
Whereas the sclerotic areas in the LFD group first appeared focally in glomeruli at 52w, 
the HFD group already exhibited these foci at 40w and displayed markedly increased 
lesions at 52 weeks. At this time point, not only glomeruli were affected, but lesions 
were also observed in the tubulo-interstitium (Fig. 4A-B). To confirm the fibrotic nature 
of the observed lesions we quantified collagen I protein, the main form of collagen 
found in mature renal fibrotic lesions, by immunohistochemistry. At 24w and 52w a 
significant difference in the extent of collagen deposition was observed between LFD 
and HFD challenged mice. However, the extent of collagen deposition in HFD mice 
did not increase proportionally to the extent of the lesions as assessed by MT staining 
Figure 3. Renal (dys)function and injury markers with aging and HFD-feeding. (A) With aging 
a significant increase in albuminuria was observed which was enhanced by HFD feeding. (B) Plasma 
blood urea nitrogen levels did not change. (C) NGAL levels showed no age-associated changes but 
were significantly increased in HFD urine samples for all time points. (D) Urinary KIM-1 levels showed 
no significant changes. Data expressed as mean ±SEM. Dotted lines represent baseline values for 
albumin (49.86 ±4.67), NGAL (1086.00 ±47.63) and KIM-1 (98.37 ±6.175). Significance level set at p<0.05. 
*=significantly different from LFD at same time point, †=significantly different from same diet 24w, 





























(Suppl. 2A-B). This finding, combined with the weak PAS staining of the lesions (Fig 
4A), prompted us to further investigate the nature of the amorphous material. We 
explored misfolded amyloidogenic protein aggregates as potential candidates. Staining 
with Congo Red (CR) in combination with microscopical assessment by polarized light, 
revealed the typical apple-green birefringence of the CR dye to be present in glomeruli 
as well as in the tubulo-interstitium (Fig 5A-B). Quantification of CR staining in the renal 
cortex showed a significant increase of amyloid deposits in both LFD and HFD mice with 
aging which was significantly greater in HFD-treated mice (Fig. 5C). There was a strong 
correlation between total body weight and the extent of amyloidosis (Fig 5D), suggesting 
Figure 4. Development of renal sclerosis with aging and HFD-feeding. Representative histological 
pictures of the renal cortex (100x) and a magnified glomerulus (inset; 400x) of mice sacrificed after 24, 
40 and 52 weeks of LFD (upper panels) versus HFD  feeding (lower panels). (A-B) Consecutive tissue 
sections stained with periodic acid Schiff’s and Masson’s trichrome demonstrate first nodular appearance 
of age-associated sclerosis at 52w in glomeruli of LFD fed mice. These nodules are advanced in HFD fed 
mice, being observed as early as 40w, and become severely aggravated at 52w, also affecting the tubulo-
interstitial area.
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Figure 5. Renal amyloid deposits with aging and HFD-feeding. (A) Representative pictures of renal LFD 
and HFD sections stained for Congo Red and (B) the same sections assessed under polarized light show 
sclerotic lesions in the renal cortex, both interstitial (100x) and glomerular (insets; 400x). (A-B) Amyloid 
first appears in glomerular regions (indicated by dotted circles) at HFD40 and extensively affects tubulo-
interstitium in HFD52. (C) Quantification of amyloidosis in glomeruli demonstrating that HFD mice are 
significantly more affected at all time points. Body weight and quantified amount of amyloid show a 
strong positive correlation (C; r=0.7419; p=0.002). Data expressed as mean ±SEM. Significance level set 
at p<0.05. *=significantly different from LFD at same time point, †=significantly different from same diet 





























a link with obesity. To determine whether the observed amyloidosis was organ specific 
or systemic, other organs were assessed by CR as well demonstrating amyloid deposits 
in small intestine, left ventricle, lung, adipose and hepatic tissues, particularly affecting 
the vasculature (Suppl. 3A-F). 
HFD-induced obesity results in chronic low-grade inflammation 
Since inflammation is considered a key contributor to the onset and progression of 
obesity-induced chronic renal disorders, we examined the sequence of inflammatory 
events and their temporal relationship with the observed pathological alterations in the 
kidney. In HFD mice, plasma levels of tumor necrosis factor alpha (TNF-α) were elevated 
from 24w onwards. Monocyte chemoattractant protein 1 (MCP-1) levels increased 
significantly with aging in both LFD and HFD groups, but this increase became evident 
earlier (40w) in HFD mice. Circulating interleukin 6 (IL-6) levels were not significantly 
increased in LFD mice and HFD mice over time relative to 24w, except for the 52w time 
point in LFD mice (Fig. 6A-C). Plasma levels of IL-1β were under the detection limit in 
all mice (data not shown).
Renal gene expression analyses revealed a significant age-dependent upregulation of 
TNF-α, MCP-1 and IL-6 mRNA of which TNF-α and MCP-1 were significantly increased 
in the HFD group at 52 weeks when compared to LFD mice (Fig. 7A-C). Moreover, renal 
mRNA expression levels of IL-1β in HFD mice increased significantly over time (Fig. 
7D). 
By immunohistochemistry, infiltration of CD68+ macrophages in glomeruli and tubulo-
interstitium was observed in both LFD and HFD mice. The number of infiltrating 
Figure 6. Systemic pro-inflammatory cytokine levels with aging and HFD-feeding. (A) Plasma levels of 
TNF-α are significantly higher in HFD mice at all time points and significantly increase in time for HFD 
mice. (B-C) MCP-1 and IL-6 levels show an age-associated increase which is advanced by HFD-feeding. 
Data expressed as mean ±SEM. Significance level set at p<0.05. *=significantly different from LFD at same 
time point, †=significantly different from same diet 24w, ‡=significantly different from same diet 40w.
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Figure 7. Renal inflammation with aging and HFD-feeding. (A-D) Renal gene expression analyses show 
an age-associated increase of TNF-α, MCP-1, IL-6 and IL-1b mRNA levels, significantly different between 
LFD and HFD for TNF-α and MCP-1 at 52w. (D-E) Representative pictures of CD68+ positive macrophages 
in renal cortex (100x) and glomerulus (inset; 400x) at different time points showing significant differences 
between LFD and HFD at 24w and 52w. Data expressed as mean ±SEM. Significance level set at p<0.05. 
*=significantly different from LFD at same time point, †=significantly different from same diet 24w, 





























macrophages in HFD mice was significantly increased at 24w and 52w when compared 
to LFD mice as quantified by morphometry (Fig. 7E-F). Moreover, CD68+ macrophage 
accumulation positively correlated with the extent of collagen I deposits (r=0.795, 
p<0.001) as assessed in matched cortical regions.
HFD-induced elevation of systemic SAA levels is associated with enhanced SAA 
amyloid deposition
Amyloidosis is caused by the extracellular deposition of protein fibrils and many 
amyloidogenic proteins have been identified. However, irrespective of the origin of the 
amyloidogenic protein, all forms of amyloidosis share common histological features23. 
In AA amyloidosis the amyloid fibrils are derived from SAA, an acute phase protein 
Figure 8. Plasma SAA concentrations and renal SAA deposition. (A) Plasma concentrations of SAA 
protein were significantly elevated in HFD mice at all time points. (B) Quantification of SAA in HDL 
showed more SAA present in HDLHFD compared to HDLLFD at 52w. (C-D) Representative renal sections 
stained with SAA antibody show distinct localization of SAA protein in the glomerulus which is more 
abundant in HFD mice. (E) Congo red and SAA double staining confirmed SAA protein and amyloid to 
localize in the same region. Data expressed as mean ±SEM. Dotted lines represent baseline value for SAA 
(7.33± 1.24 ng/ml). Significance level set at p<0.05. *=significantly different from LFD same time point.
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produced by hepatocytes under inflammatory conditions 24. Since obesity induced a state 
of low grade chronic inflammation, we postulated that the observed renal amyloidosis 
in our study originated from SAA deposits due to chronically elevated levels of 
SAA. Systemic SAA levels were significantly higher in HFD mice during the entire 
investigational period (Fig. 8A).
Besides its free form, SAA is predominantly found associated with high-density 
lipoproteins (HDL)25. Examination of the presence of SAA in the HDL fractions of pooled 
plasma samples showed HDLHFD to contain a higher amount of SAA than HDLLFD (Fig. 
8B). In addition, by immunohistochemistry,   positive staining for SAA in glomeruli 
and tubulo-interstitium (not shown) was observed in both LFD and HFD mice (Fig. 8C) 
which was significantly more extensive in HFD mice (Fig. 8D). Finally, combining CR 
with SAA staining, a strong co-localization of amyloid deposits and SAA was observed 
(Fig 8E).
DISCUSSION
The current study was designed to provide insight into the evolution of both obesity- and 
age-associated renal pathologies. In C57BL/6J mice fed a LFD or a HFD, we investigated 
when and how renal pathology manifests at the functional and systemic level and how 
this associates with obesity and age-dependent inflammation. We demonstrate a gradual, 
age-dependent occurrence of mild albuminuria, tubulo-interstitial and glomerular 
structural changes, and increased expression of inflammatory mediators. When 
superimposed with a HFD, albuminuria and renal inflammation were detected earlier 
and increased in extent. Most strikingly, compared to LFD mice, HFD mice developed 
severely aggravated structural and morphological changes that showed features typical 
of amyloidosis.
Age-associated glomerulosclerosis with amyloid characteristics and ectopic lipid 
depositions was previously described in C57BL/6J mice 16. Our study extends these 
observations by disseminating the development of this age-related phenotype over 
time and analyzing its association with the development of albuminuria and renal 
inflammatory parameters. More importantly, our study allowed examination of the 
detrimental effects caused by prolonged obesity superimposed to aging. Obesity has 
been shown to advance the appearance of many age-associated diseases including 
CKD 26,27. Hence it is often referred to as an accelerating factor of the aging process 28. 
Inflammation is known to negatively influence many age-associated processes, hence 
the systemic inflammation that accompanies obesity has been considered a driving factor 
behind this accelerated aging phenotype 29. Indeed, our data demonstrate that obesity, 





























and aggravates the functional and structural abnormalities in the kidneys as evidenced 
by increased albuminuria and extensive glomerular and tubulo-interstitial lesions in 
mice fed a HFD.
The enhanced renal inflammatory phenotype observed with obesity may have multiple 
origins. First, because the lipid storing capacity of the adipose tissue (AT) and liver 
is exceeded with obesity, lipid uptake from the circulation is impaired resulting in 
hyperlipidemia 30,31. Consequently, lipid uptake in the kidneys may be enhanced 
causing lipotoxicity and inflammation 32. Second, obesity induced by HFD feeding 
may cause insulin resistance (IR) leading to systemic hyperglycemia which is known 
to be associated with endothelial dysfunction and enhanced renal inflammation 33,34. 
Furthermore, prolonged hyperglycemia is known to provoke hypertension 35,36, which 
in the kidney glomerulus can lead to hyperfiltration and inflammation. Whereas in our 
study mice did not develop hyperglycemia or signs of hypertension, we did observe 
a rise in plasma lipids. This was evident as illustrated by elevated plasma cholesterol 
levels in HFD mice from 24 weeks onwards and elevated triglycerides levels from 40w 
onwards. The latter was paralleled by glomerular lipid accumulation (data not shown). 
These data suggest that the enhanced inflammatory phenotype in the HFD mice is likely 
linked to hyperlipidemia. 
Previously, we have reported that excessive adiposity is associated with AT 
inflammation 17. Prolonged AT inflammation has been shown to enhance systemic 
release of pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β 12 that may 
cause endothelial activation thereby promoting leukocyte recruitment in the kidney. 
In the current study we particularly detected increased circulating levels of TNF-α in 
HFD mice. Compared to LFD mice increased circulating levels of TNF-α were already 
detectable in HFD mice at 24w, were consistently elevated over time and were associated 
with increased numbers of renal macrophages (Mφ). 
Mφ are known to promote deposition of collagen I 14. Indeed, here Mφ accumulation 
strongly correlated with collagen I deposition. Interestingly, however, collagen deposition 
did not increase proportionally with the marked glomerular and tubulo-interstitial 
lesions observed by MT staining. Further analysis revealed that obesity promoted the 
deposition of amyloid, rather than collagen in the kidney in this strain of C57BL/6J mice 
and prompted us to investigate a potential link between obesity and amyloidosis. 
Renal amyloidosis is a rare but severe disease with poor prognosis in which misfolded 
proteins aggregate to form extracellular fibrillary depositions that destruct the glomerular 
and tubular architecture 37,38. The initiation and progression of some forms of amyloidosis 
is driven by proteins involved in chronic inflammatory processes leading to secondary 
amyloidosis 39. Here, we found SAA to be a major constituent of the amyloid depositions 
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in kidneys of both LFD and HFD mice. Together with our observations of amyloidosis in 
other organs, emphasizing the systemic nature of the disease, it may be best classified as 
AA amyloidosis (AA). Interestingly, systemic SAA levels in HFD mice were increased as 
well suggesting that obesity, via induction of enhanced SAA production, can provoke or 
accelerate the process of amyloidosis. 
SAA is an acute phase protein that preferentially associates with High Density 
Lipoprotein (HDL) 30. SAA is thought to enhance HDL’s affinity for cholesterol laden 
Mφ 40, directing the HDL particle to sites of Mφ accumulation. On reaching the Mφ, SAA 
is separated from the HDL particle 41 which under conditions of chronic Mφ accumulation 
could promote an increase in local SAA levels and potentially favor amyloidogenesis. 
We indeed detected enhanced SAA protein in the HDL fraction of HFD mice. This, in 
conjunction with chronically increased renal Mφ in HFD mice, suggests that such a 
mechanism may have contributed to the development of amyloid deposits. 
With respect to the source of SAA in obesity, at least two non-mutually exclusive 
possibilities can be proposed. First, the adipose tissue itself has been identified as a 
source of SAA in obesity 42–45. However, it remains debated whether AT-derived SAA 
can be secreted. More likely, obesity induced chronic production of pro-inflammatory 
cytokines, in particular TNF-α, may stimulate hepatocytes to overproduce SAA 46. 
Fig. 9 summarizes the conceptual axis along which HFD-feeding could lead to amyloid 
deposits in the glomerular vasculature considering SAA to be of hepatic origin. 
Figure 9. Proposed conceptual link between high-fat diet feeding and renal amyloidosis. HFD-feeding 
results in an excess of circulating triglycerides which are primarily stored in the adipose tissue (AT). To 
cope with excess triglycerides the adipocytes increase both in size and number. Eventually, inadequate 
oxygenation and lipotoxicity will trigger local inflammatory pathways, thereby promoting the recruitment 
of macrophages (Mφ) to the AT. Infiltrating Mφ enhance the local production of pro-inflammatory factors, 
which eventually enter the circulation and lead to systemic low-grade inflammation (LGI). In parallel, 
as the AT has insufficient lipid storage capacity, TGs spill over to the circulation leading to systemic 
hyperlipidemia. Both LGI and hyperlipidemia may promote macrophage recruitment in a variety of 
vasculatures including  the glomerular microvasculature.
Systemic AT-derived cytokines, in particular TNF-α, also affect the liver. TNF-α stimulates the production 
of serum amyloid A (SAA), an acute phase inflammatory reactant which, upon entering the circulation, 
associates with high density lipoprotein (HDL). Binding of SAA to HDL is thought to target the HDL 
particle to sites where macrophages accumulate; in this case the glomerular microvasculature. 
Although it is  unclear what happens with SAA once HDL reaches the inflammatory site, it likely dissociates 
and temporarily resides in the tissue. Therefore, as in HFD-induced obesity chronic inflammation is 
unresolved, the local concentration of SAA can significantly increase. These high concentrations favor 
SAA’s amyloidogenic properties, i.e. promote its misfolding and aggregation. As this process progresses 































To date, little clinical or experimental evidence exists on a causal link between obesity 
and AA amyloidosis. However, in case reports patients have been described in which 
morbid obesity was considered the sole remaining cause of renal AA 42,47. In addition, 
a recent study in genetically obese Ob/Ob mice demonstrated the occurrence of SAA 
depositions upon injection with amyloid enhancing factor (AEF)48, emphasizing the 
potential of obesity induced SAA to form amyloid.
Chronically elevated SAA levels are a key prerequisite for AA amyloidosis. However, the 
approximately 3-fold increase in SAA levels observed in HFD mice, which is similar to 
those reported in obese humans 42, contrasts markedly with the approximately 100-fold 
induction of SAA in for example RA patients 49. Moreover, LFD mice also developed 
amyloidosis, albeit at a later time point and to a lesser extent, but without an overt 
increase in circulating SAA levels. This suggests that other factors must be present that 
favor local accumulation of SAA over time. Recent studies in a mouse model of senile 
amyloidosis showed endoplasmatic reticulum stress and autophagy to be associated 
with apoptosis and extracellular deposition of the amyloidogenic ApoA2 lipoprotein 50. 
Whereas such mechanisms may be involved in SAA accumulation as well, at present 
we cannot fully explain the age-dependent development of amyloidosis. Interestingly, 
background strain and animal supplier may be important determinants as well 16. This 
suggests that susceptibility to develop the age-dependent amyloidosis is genetically 
determined. Comparing the genome of this strain with C57Bl/6 mice from other 
suppliers offers a possibility to further elucidate the underlying molecular mechanism of 
this age-dependent renal phenotype, and perhaps its relevance for human CKD.
Our study has several limitations. To minimize confounding factors, we performed this 
study in mice with strictly defined diets that only differed in fat content. The Western 
style diet of humans is of course more complex being also high in protein, cholesterol, 
fructose, and salt. Overabundance of all of these dietary factors has been implicated in 
the detrimental effects of obesity as well 51–54. Moreover, our study was designed as an 
observational study intended to characterize and monitor the evolution of structural 
alterations in the kidney in conjunction with renal function and temporal changes in 
metabolic and inflammatory factors. Since our study did not include specific interventions 
we can only speculate on potential mechanisms involved based on associations. Despite 
these limitations, the data presented here demonstrate that obesity-induced systemic 
inflammation plays a crucial role in the progression of age-dependent renal dysfunction 
and structural injury. In particular, our study indicates obesity as a potential risk factor 
for the development of AA amyloidosis at least in susceptible individuals. Future studies 
on the role of SAA, and its association with the HDL particle in the course of obesity are 































We acknowledge  Davith de Vries for his work on the amyloid phenotype, Danny Kor, 
Marjo van de Waarenburg, Henk Moorlag and Karin Toet for their laboratory assistance, Inge 
Vreeswijk Baudoin for her help on hemodynamic measurements, and Peter Zwiers and 
Arjen Petersen for their technical assistance on the animal experiments. In addition we 
thank Dr. Eliana Popa for her valuable advice while writing the manuscript. 
AUTHOR CONTRIBUTIONS
RvdH, PH, RK and GY designed the study. RvdH, JB, and WM performed the experiments 
and were responsible for data acquisition and analysis. RvdH, PH, RdB, RK, TN, BH, CS 
and UT interpreted the data and RvdH and PH wrote the manuscript. All authors were 
involved in critical revision of the drafted manuscript and approved the final version.
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
FUNDING
This study was funded by the Top Institute for Food and Nutrition (TIFN), a public-
private partnership on pre-competitive research in food and nutrition. The funders had 




1. Zhou, X. J. et al. The aging kidney. Kidney Int. 74, 
710–720 (2008).
2. Kaplan, C., Pasternack, B., Shah, H. & Gallo, G. 
Age-related incidence of sclerotic glomeruli in 
human kidneys. Am. J. Pathol. 80, 227–234 (1975).
3. Coresh, J., Astor, B. C., Greene, T., Eknoyan, G. & 
Levey, A. S. Prevalence of chronic kidney disease 
and decreased kidney function in the adult US 
population: Third National Health and Nutrition 
Examination Survey. Am. J. Kidney Dis. 41, 1–12 
(2003).
4. Rule, A. D. et al. The association between age and 
nephrosclerosis on renal biopsy among healthy 
adults. Ann. Intern. Med. 152, 561–567 (2010).
5. Vorster, H. H., Bourne, L. T., Venter, C. S. & 
Oosthuizen, W. Contribution of Nutrition to the 
Health Transition in Developing Countries: A 
Framework for Research and Intervention. Nutr. 
Rev. 57, 341–349 (1999).
6. Popkin, B. M., Adair, L. S. & Ng, S. W. NOW AND 
THEN: The Global Nutrition Transition: The 
Pandemic of Obesity in Developing Countries. 
Nutr. Rev. 70, 3–21 (2012).
7. Collins, A. J. et al. US renal data system 2011 
Annual data report. Am. J. Kidney Dis. 59, 6386 
(2012).
8. Foley, R. N. & Collins, A. J. The USRDS: What you 
need to know about what it can and can’t tell us 
about ESRD. Clin. J. Am. Soc. Nephrol. 8, 845–851 
(2013).
9. Oberg, B. P. et al. Increased prevalence of oxidant 
stress and inflammation in patients with moderate 
to severe chronic kidney disease. Kidney Int. 65, 
1009–1016 (2004).
10. Hotamisligil, G. S. Inflammation and metabolic 
disorders 1. Nature 444, 860–867 (2006).
11. Vlassara, H. et al. Role of oxidants/inflammation 
in declining renal function in chronic kidney 
disease and normal aging. Kidney Int. Suppl. 76, 
S3–S11 (2009).
12. Wellen, K. E. & Hotamisligil, G. S. Obesity-induced 
inflammatory changes in adipose tissue. J. Clin. 
Invest. 112, 1785–1788 (2003).
13. Norris, A. L. et al. Circulating oxidized LDL and 
inflammation in extreme pediatric obesity. Obesity 
(Silver Spring). 19, 1415–1419 (2011).
14. Liu, Y. Renal fibrosis: new insights into the 
pathogenesis and therapeutics. Kidney Int. 69, 213–
217 (2006).
15. Wahba, I. M. & Mak, R. H. Obesity and obesity-
initiated metabolic syndrome: Mechanistic links to 
chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2, 
550–562 (2007).
16. Schmitt, R. et al. Ageing mouse kidney--not always 
the SAME old story. Nephrol. Dial. Transplant 24, 
3002–3005 (2009).
17. van der Heijden, R. A. et al. High fat diet induced 
obesity primes inflammation in adipose tissue 
prior to liver in C57BL/6j mice. Aging (Albany NY) 
7, 256–268 (2015).
18. Meems, L. M. G. et al. The vitamin D receptor 
activator paricalcitol prevents fibrosis and diastolic 
dysfunction in a murine model of pressure 
overload. J. Steroid Biochem. Mol. Biol. 132, 282–289 
(2012).
19. Yakala, G. K. et al. Beneficial Effects of an 
Alternating High- Fat Dietary Regimen on 
Systemic Insulin Resistance, Hepatic and Renal 
Inflammation and Renal Function. PLoS One 7, 
(2012).
20. Sipe, J. D. et al. Amyloid fibril protein 
nomenclature: 2010 recommendations from the 
nomenclature committee of the International 
Society of Amyloidosis. Amyloid 17, 101–104 (2010).
21. Puchtler, H., Sweat, F. & Levine, M. ON THE 
BINDING OF CONGO RED BY AMYLOID. J. 
Histochem. Cytochem. 10, 355–364 (1962).
22. Tietge, U. J. F. et al. Lipids and Lipoproteins: 
Overexpression of Secretory Phospholipase A2 
Causes Rapid Catabolism and Altered Tissue 
Uptake of High Density Lipoprotein. 275, 10077–
10084 (2000).
23. Westermark, P. et al. A primer of amyloid 
nomenclature. Amyloid 14, 179–183 (2007).
24. Malle, E. & De Beer, F. C. Human serum amyloid 
A (SAA) protein: a prominent acute-phase reactant 
for clinical practice. Eur. J. Clin. Invest. 26, 427–435 
(1996).
25. Tietge, U. J. F. et al. Human secretory 
phospholipase A2 mediates decreased plasma 
levels of HDL cholesterol and ApoA-I in response 
to inflammation in human ApoA-I transgenic 
mice. Arterioscler. Thromb. Vasc. Biol. 22, 1213–1218 
(2002).
26. Hall, J. E. et al. Is Obesity a Major Cause of Chronic 
Kidney Disease? Advances in Renal Replacement 
Therapy 11, 41–54 (2004).
27. Kramer, H. Obesity and chronic kidney disease. 
Contributions to Nephrology 151, 1–18 (2006).
28. Tzanetakou, I. P., Katsilambros, N. L., Benetos, A., 
Mikhailidis, D. P. & Perrea, D. N. Is obesity linked 
to aging? Adipose tissue and the role of telomeres. 
Ageing Res. Rev. 11, 220–229 (2012).
29. Carlsen, H. et al. Diet-induced obesity increases 
NF-κB signaling in reporter mice. Genes Nutr. 4, 
215–222 (2009).
30. Kisilevsky, R. & Tam, S. Acute phase serum amyloid 
a, cholesterol metabolism, and cardiovascular 






























31. Tan, C. Y. & Vidal-Puig, A. Adipose tissue 
expandability: the metabolic problems of obesity 
may arise from the inability to become more obese. 
Biochem. Soc. Trans. 36, 935–940 (2008).
32. Jiang, T. et al. Diet-induced obesity in C57BL/6J 
mice causes increased renal lipid accumulation 
and glomerulosclerosis via a sterol regulatory 
element-binding protein-1c-dependent pathway. J. 
Biol. Chem. 280, 32317–32325 (2005).
33. Schrijvers, B. F., De Vriese, A. S. & Flyvbjerg, A. 
From hyperglycemia to diabetic kidney disease: 
The role of metabolic, hemodynamic, intracellular 
factors and growth factors/cytokines. Endocrine 
Reviews 25, 971–1010 (2004).
34. Garud, M. S. & Kulkarni, Y. A. Hyperglycemia to 
Nephropathy via Transforming Growth Factor 
Beta. Curr. Diabetes Rev. 10, 182–9 (2014).
35. DeFronzo, R. A. & Ferrannini, E. Insulin 
Resistance: A Multifaceted Syndrome Responsible 
for NIDDM, Obesity, Hypertension, Dyslipidemia, 
and Atherosclerotic Cardiovascular Disease. 
Diabetes Care 14, 173–194 (1991).
36. Paneni, F., Beckman, J. A., Creager, M. A. & 
Cosentino, F. Diabetes and vascular disease: 
pathophysiology, clinical consequences, and 
medical therapy: part I. Eur. Heart J. 34, 2436–43 
(2013).
37. Dember, L. M. Amyloidosis-associated kidney 
disease. J. Am. Soc. Nephrol. 17, 3458–3471 (2006).
38. Bollée, G. et al. Presentation and outcome of 
patients with systemic amyloidosis undergoing 
dialysis. Clin. J. Am. Soc. Nephrol. 3, 375–381 (2008).
39. Lachmann, H. J. et al. Natural history and outcome 
in systemic AA amyloidosis. N. Engl. J. Med. 356, 
2361–2371 (2007).
40. Kisilevsky, R. & Subrahmanyan, L. Serum amyloid 
A changes high density lipoprotein’s cellular 
affinity. A clue to serum amyloid A’s principal 
function. Lab. Invest. 66, 778–785 (1992).
41. Tam, S. P., Kisilevsky, R. & Ancsin, J. B. Acute-
phase-HDL remodeling by heparan sulfate 
generates a novel lipoprotein with exceptional 
cholesterol efflux activity from macrophages. PLoS 
One 3, (2008).
42. Poitou, C. et al. Serum amyloid A: Production by 
human white adipocyte and regulation by obesity 
and nutrition. Diabetologia 48, 519–528 (2005).
43. den Hartigh, L. J. et al. Deletion of Serum Amyloid 
A3 Improves High Fat High Sucrose Diet-Induced 
Adipose Tissue Inflammation and Hyperlipidemia 
in Female Mice. PLoS One 9, e108564 (2014).
44. Yang, R. Z. et al. Acute-phase serum amyloid A: 
An inflammatory adipokine and potential link 
between obesity and its metabolic complications. 
PLoS Med. 3, 0884–0894 (2006).
45. Zhao, Y. et al. Association between serum amyloid 
A and obesity: A meta-analysis and systematic 
review. Inflamm. Res. 59, 323–334 (2010).
46. Shibasaki, T. et al. A case of renal amyloidosis 
associated with hepatic adenoma: the pathogenetic role 
of tumor necrosis factor-alpha. Nephron 75, 350–353 
(1997).
47. Alsina, E., Martin, M., Panadés, M. & Fernández, 
E. Renal AA amyloidosis secondary to morbid obesity? 
Clinical nephrology 72, 312–314 (2009).
48. Barbara Kluve-Beckerman, Lijing Du, J. H. 
Obesity as a determinant in the development and 
progression of AA amyloidosis. Abstr. XIVth Int. 
Symp. Amyloidoisis
49. Targońska-Stępniak, B. & Majdan, M. Serum 
Amyloid A as a Marker of Persistent Inflammation 
and an Indicator of Cardiovascular and Renal 
Involvement in Patients with Rheumatoid 
Arthritis. Mediators Inflamm. 2014, 1–7 (2014).
50. Luo, H. et al. Extracellular deposition of mouse 
senile AApoAII amyloid fibrils induced different 
unfolded protein responses in the liver, kidney, 
and heart. Lab. Investig. 95, 320–333 (2014).
51. Wheeler, D. C. & Bernard, D. B. Lipid abnormalities 
in the nephrotic syndrome: causes, consequences, 
and treatment. Am. J. Kidney Dis. 23, 331–346 
(1994).
52. Mcmahon, E., Campbell, K., Bauer, J. & Mudge, D. 
Altered dietary salt intake for people with chronic 
kidney disease ( Review ). (2015).
53. Karalius, V. P. & Shoham, D. A. Dietary Sugar and 
Artificial Sweetener Intake and Chronic Kidney 
Disease: A Review. Advances in Chronic Kidney 
Disease 20, 157–164 (2013).
54. Martin, W. F., Armstrong, L. E. & Rodriguez, N. 
R. Dietary protein intake and renal function. Nutr. 
Metab. (Lond). 2, 25 (2005).
70 
SUPPLEMENTARY MATERIAL
Supplementary Figure S1. Left ventricle hemodynamic and gene expression parameters. (A) Left 
ventricle (LV) systolic and diastolic blood pressure (SBP and DBP). (B) LV weight corrected for tibia 
length. (C) Ventricular contractility. Expression of (D) inflammatory, (E) fibrotic and (F) injury genes in 
LV. Data expressed as mean ±SEM. Significance level set at p<0.05. *=significantly different from LFD 





























Supplementary Figure S2. Cortical collagen I protein expression with aging and HFD-feeding. (A) 
Representative overviews of the renal cortex (100x) and individual glomeruli (inset; 400x) from collagen 
I stained sections. (B) Quantification of staining shows significantly elevated collagen I protein in HFD 
groups at 24 and 52 weeks, but no significant change over time for HFD mice. Data expressed as mean 
±SEM. Significance level set at p<0.05. *=significantly different from LFD same time point, ‡=significantly 
different from same diet 40w.
72 
Supplementary Figure S3. Congo Red staining of (A) small intestine, (B) lung, (C) left ventricle, (D) 
adipose and (E) hepatic tissue sections, assessed under brightfield (A-E) and polarized light (F-J) showing 
























































*	  =	  20h	  Urine	  collection (2w	  prior	  to sacrifice,	  all animals)
Kidneys
Morphology (PAS,	  MT,	  Collagen I,	  CD68)
Gene	  expression (Tnf,	  Mcp-­‐1,	  IL-­‐6,	  IL-­‐1β)
Whole Blood






Supplementary Figure S4. Experimental design.

